Table 5.
Yearly and overall AWD
| Therapy | Cohort | AWD | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall | 2015 | 2016 | 2017 | ||||||||||
| Mean | SD | Median | Mean | SD | Median | Mean | SD | Median | Mean | SD | Median | ||
| DULA | BE N = 389 | 1.52 | 0.18 | 1.48 | 1.47 | 0.06 | 1.48 | 1.56 | 0.23 | 1.50 | |||
| BE 0.75 mg N = 54 | 1.13 | 0.23 | 1.14 | 0.97 | 0.19 | 1.01 | 1.28 | 0.15 | 1.28 | ||||
| BE 1.5 mg N = 335 | 1.58 | 0.17 | 1.54 | 1.56 | 0.06 | 1.55 | 1.60 | 0.23 | 1.53 | ||||
| FR N = 3464 | 1.43 | 0.08 | 1.42 | 1.44 | 0.03 | 1.43 | 1.43 | 0.11 | 1.40 | ||||
| FR 0.75 mg N = 433 | 0.76 | 0.04 | 0.75 | 0.76 | 0.02 | 0.76 | 0.77 | 0.05 | 0.75 | ||||
| FR 1.5 mg N = 3031 | 1.53 | 0.09 | 1.51 | 1.53 | 0.04 | 1.53 | 1.53 | 0.13 | 1.49 | ||||
| DE N = 23,039 | 1.49 | 0.13 | 1.45 | 1.45 | 0.03 | 1.46 | 1.44 | 0.02 | 1.45 | 1.57 | 0.21 | 1.47 | |
| DE 0.75 mg N = 5,837 | 1.21 | 0.16 | 1.19 | 1.05 | 0.12 | 1.11 | 1.19 | 0.02 | 1.18 | 1.37 | 0.11 | 1.33 | |
| DE 1.5 mg N = 17,202 | 1.59 | 0.21 | 1.54 | 1.55 | 0.06 | 1.57 | 1.53 | 0.03 | 1.54 | 1.69 | 0.34 | 1.52 | |
| IT N = 5795 | 1.53 | 0.13 | 1.51 | 1.50 | 0.12 | 1.52 | 1.56 | 0.15 | 1.51 | ||||
| IT 0.75 mg N = 394 | 1.09 | 0.20 | 1.09 | 0.97 | 0.07 | 0.97 | 1.20 | 0.22 | 1.14 | ||||
| IT 1.5 mg N = 5401 | 1.56 | 0.14 | 1.55 | 1.53 | 0.13 | 1.56 | 1.59 | 0.14 | 1.54 | ||||
| NL N = 180 | 1.53 | 0.10 | 1.51 | 1.56 | 0.13 | 1.52 | 1.50 | 0.07 | 1.51 | 1.53 | 0.11 | 1.51 | |
| NL 0.75 mg N = 30 | 1.36 | 0.27 | 1.41 | 1.19 | 0.31 | 1.02 | 1.31 | 0.31 | 1.23 | 1.52 | 0.04 | 1.50 | |
| NL 1.5 mg N = 150 | 1.55 | 0.10 | 1.53 | 1.59 | 0.12 | 1.55 | 1.54 | 0.04 | 1.54 | 1.53 | 0.11 | 1.51 | |
| CA N = 1782 | 1.25 | 0.13 | 1.26 | 1.15 | 0.08 | 1.18 | 1.35 | 0.09 | 1.33 | ||||
| CA 0.75 mg N = 1229 | 1.15 | 0.17 | 1.18 | 1.00 | 0.07 | 1.02 | 1.29 | 0.10 | 1.27 | ||||
| CA 1.5 mg N = 553 | 1.53 | 0.13 | 1.49 | 1.55 | 0.15 | 1.51 | 1.51 | 0.11 | 1.48 | ||||
| exQW | BE N = 1058 | 2.14 | 0.14 | 2.12 | 2.17 | 0.07 | 2.19 | 2.11 | 0.07 | 2.09 | 2.14 | 0.22 | 2.09 |
| FR N = 3111 | 2.03 | 0.12 | 2.00 | 2.05 | 0.06 | 2.02 | 2.00 | 0.02 | 2.00 | 2.06 | 0.19 | 2.00 | |
| DE N = 2181 | 2.08 | 0.13 | 2.04 | 2.07 | 0.05 | 2.08 | 2.02 | 0.05 | 2.04 | 2.15 | 0.19 | 2.04 | |
| IT N = 4346 | 2.09 | 0.12 | 2.07 | 2.10 | 0.05 | 2.09 | 2.06 | 0.03 | 2.06 | 2.12 | 0.20 | 2.06 | |
| NL N = 86 | 2.07 | 0.17 | 2.06 | 2.08 | 0.18 | 2.06 | 2.03 | 0.13 | 2.06 | 2.09 | 0.21 | 2.07 | |
| CA N = 356 | 2.09 | 0.10 | 2.08 | 2.11 | 0.14 | 2.11 | 2.08 | 0.06 | 2.07 | ||||
AWD presented represents a summary of monthly AWD for eligible prescription records. Patient N changes over time, and patients reflect a mix of new initiators and prevalent users over time
AWD reported for ExQW (mg) and DULA (mg). AWD calculated as ADD × 7
BE Belgium, CA Canada, DULA dulaglutide, exQW exenatide once weekly, FR France, DE Germany, IT Italy, mg milligrams, NL Netherlands